Diagnóstico del hiperparatiroidismo primario

  1. Manuel Delgado-Gómez 1
  2. Sonsoles De La Hoz-Guerra 2
  3. María Garcia-Duque 1
  4. María Vega-Blanco 1
  5. Irune Blanco-Urbaneja 1
  1. 1 Hospital Universitario de Salamanca
    info

    Hospital Universitario de Salamanca

    Salamanca, España

    ROR https://ror.org/0131vfw26

  2. 2 Atención Primaria. Área de Salud de Béjar. Salamanca
Revista:
Revista ORL

ISSN: 2444-7986,  2444-7986

Año de publicación: 2020

Volumen: 11

Volumen: 3

Páginas: 347-359

Tipo: Artículo

DOI: 10.14201/ORL.21428 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: Revista ORL

Resumen

Introducción y objetivo: Describir la etiopatogenia y el diagnóstico diferencial entre el hiperparatiroidismo primario y otras causas de hipercalcemia. Síntesis: El hiperparatiroidismo primario (HPP) es una enfermedad endocrina frecuente, que se define de forma convencional como la existencia de hipercalcemia en presencia de niveles elevados de hormona paratiroidea (PTH). Aunque la forma más común de presentación en la actualidad sea como hipercalcemia asintomática, la elevada morbilidad asociada con esta patología requiere que se realice un diagnóstico precoz y preciso, tanto de la etiología como de sus complicaciones, para poder llevar a cabo un manejo adecuado de los pacientes afectados.

Referencias bibliográficas

  • Bilezikian JP. Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2018; 103(11):3993-4004.
  • Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99(10): 3561-69.
  • Bilezikian JP, Khan AA, Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94(2):335-9.
  • Cerdà D, Peris P, Monegal A, Albaladejo C, Martínez de Osaba MJ, Surís X, Guañabens N. Increase of PTH in post-menopausal osteoporosis. Rev Clin Esp. 2011; 211(7):338-43.
  • Christensen SE, Nissen PH, Vestergaard P, Mosekilde L. Familial hypocalciuric hypercalcaemia: a review. Curr Opin Endocrinol Diabetes Obes. 2011; 18(6):359-70
  • Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest. 1973; 52(1):134-42.
  • Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013; 16(1):33-9.
  • Dimkovic NB, Wallele AA, Oreopoulos DG. Renal stone disease, elevated iPTH level and normocalcemia. Int Urol Nephrol. 2002; 34(1):135-41.
  • Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ 3rd, Wermers RA. Thiazide- Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades. J Clin Endocrinol Metab. 2016; 101(3):1166-73.
  • Haden ST, Brown EM, Hurwitz S, Scott J, El-Hajj Fuleihan G. The effects of age and gender on parathyroid hormone dynamics. Clin Endocrinol (Oxf). 2000; 52(3):329-38.
  • Insogna KL. Primary Hyperparathyroidism. N Engl J Med. 2018; 379(11):1050-9.
  • Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med. 2011; 365(25):2389-97.
  • Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003; 88(10):4641-8.
  • McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354(8):821-31.
  • Meehan AD, Udumyan R, Kardell M, Landén M, Järhult J, Wallin G. Lithium-Associated Hypercalcemia: Pathophysiology, Prevalence, Management. World J Surg. 2018; 42(2):415-24
  • Mismar AA, Materazzi G, Biricotti M, Albsoul NM, Younes NA, Miccoli P. Performance of chloride/ phosphate test in patients with primary hyperparathyroidism. Is it related to calcium level? Saudi Med J. 2013; 34(8):801-5.
  • Muñoz Torres M, Jodar Gimeno E, Reyes Garcia R, Martínez Diaz Guerra G, Amado JA, Gaztambide S, Quesada Gómez JM; Calcium Study Group. Results from a national survey on the management of primary hyperparathyroidism. J Endocrinol Invest. 2012; 35(11):957-63.
  • Muñoz-Torres M, García-Martín A. Primary hyperparathyroidism. Med Clin (Barc). 2018; 150(6):226-32.
  • Silverberg SJ, Shane E, Jacobs TP, Siris ES, Gartenberg F, Seldin D, Clemens TL, Bilezikian JP. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med. 1990; 89(3):327- 34.
  • Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998; 338(12):777-83.
  • Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 2001; 38(Pt 6):608-23.
  • Walker MD, Dempster DW, McMahon DJ, Udesky J, Shane E, Bilezikian JP, Silverberg SJ. Effect of renal function on skeletal health in primary hyperparathyroidism. J Clin Endocrinol Metab. 2012; 97(5):1501-7.
  • Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018; 14(2):115- 25.
  • Wang Q, Li X1, Chen H1, Yu H1, Li L1, Yin J1, Zhou J1, Li M1, Li Q1, Han J2, Wei L3, Liu F1, Bao Y1, Jia W1. The chloride/phosphate ratio combined with alkaline phosphatase as a valuable predictive marker for primary hyperparathyroidism in Chinese individuals. Sci Rep. 2017; 7(1):4868.
Fuente de los datos: Dialnet